Money Matters, Simplified.
Elan
Why the Street Should Love Teva Pharmaceutical's Earnings
Wed, 12/15/2010 - 11:20 by Seth Jayson
 Although business headlines still tout earnings numbers, many investors have moved past net earnings as a measure of a company's economic output. That's because earnings are very often less trustworthy than cash flow, since earnings are more open to manipulation based on dubious judgment calls. |
Teva Is Running Scared
Sat, 11/27/2010 - 10:30 by Anders Bylund
 Chief medical Fool Brian Orelli thinks that newly approved multiple sclerosis drug Gilenya from Novartis (NYSE: NVS) might not grab much of the MS therapy market after all. But Teva Pharmaceutical (Nasdaq:TEVA), which makes established MS drug Copaxone, seems to be shaking in its boots. 2010 UCLICK L.L.C. |
Are Elan's Margins Missing the Grade?
Fri, 11/12/2010 - 22:18 by Seth Jayson
 Margins matter. The more Elan (NYSE: ELN) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. Healthy margins often separate pretenders from the best stocks in the market. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Elan's competitive position could be. |
The 3 Words Every Biotech Investor Wants to Hear
Thu, 10/28/2010 - 22:44 by Brian Orelli
 "Cash flow positive!" -- three little words that are music to biotech investors' ears. |
Are You Satisfied With These Margins?
Fri, 09/03/2010 - 11:27 by Seth Jayson
 Margins matter. The more Elan (NYSE: ELN) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders. That's why I check on my holdings' margins at least once a quarter. I'm looking for the absolute numbers, comparisons to sector peers and competitors, and any trend that may tell me how strong Elan's competitive position could be. |
|